JERSEY CITY, N.J., Sept. 8, 2011 /PRNewswire/ -- Aoxing Pharmaceutical (AMEX: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing and distribution of narcotic and pain-management products, today announced that the Company will be presenting at the Rodman & Renshaw Annual Global Investment Conference China Track.
Mr. Zhenjiang Yue, Chairman and CEO, and Mr. Bob Ai, Chief Financial Officer, will present at 9:35 AM local time on Monday, September 12, 2011 at The Waldorf Astoria in New York City. Mr. Yue and Mr. Ai will provide a review of recent pipeline developments, international collaborations, upcoming milestones, and financial progress of Aoxing Pharma.
About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA). It has a joint venture collaboration with Johnson Matthey Plc to produce and market narcotics and neurological drugs in China. It also has strategic alliance partnerships with QRxPharma, Phoenix PharmaLabs, Inc and American Oriental Bioengineering, Inc. For more information, please visit: www.aoxingpharma.com.
Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc
Certain statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended June 30, 2010, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
Aoxing Pharmaceutical Company: Bob Ai Chief Financial Officer 646-367-1767 firstname.lastname@example.org
Investor Relations: The Trout Group Brian Korb 646-378-2923
SOURCE Aoxing Pharmaceutical Company, Inc.